COVID19 infection in a patient undergoing treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH) with Ravulizumab.

Shikdar, Sufana; Borogovac, Azra; Mohamad, Elabdallah; Khawandanah, Mohamad

Shikdar, Sufana; Borogovac, Azra; Mohamad, Elabdallah; Khawandanah, Mohamad.

Afiliação

Shikdar S; Department of Hematology/Oncology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, 73104, Oklahoma City, United States, OK. Sufana.shikdar@gmail.com.
Borogovac A; Hematology/Oncology fellow, Department of Medicine, Division of Hematology-Oncology Stephenson Cancer Center, University of Oklahoma Health Sciences Center, 800 NE 10th St., 6th Floor, OK, 73104, Oklahoma City, United States. Sufana.shikdar@gmail.com.
Mohamad E; Department of Hematology/Oncology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, 73104, Oklahoma City, United States, OK.
Khawandanah M; Department of Internal Medicine, University of Oklahoma Medical Center (OUMC), 73104, Oklahoma City, United States, OK.

Thromb J ; 19(1): 75, 2021 Oct 21.

Article em En | MEDLINE | ID: mdl-34674707

Palavras-chave

COVID19; Complement inhibitor; Paroxysmal nocturnal hemoglobinuria

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Thromb J Ano de publicação: 2021 Tipo de documento: Article País de publicação: Reino Unido

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google